Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study

  title={Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study},
  author={Joseph Biederman and Annika Lindst{\'e}n and Lasse Breuning Sluth and Maria Louise Petersen and Anders Ettrup and Hanne-Lise Falgreen Eriksen and Maurizio Fava},
  journal={Journal of Psychopharmacology},
  pages={511 - 521}
Background: Stimulants remain the mainstay of treatment for attention-deficit hyperactivity disorder (ADHD) but are often associated with insufficient response or poor tolerability, leading to many patients not wishing to be treated with controlled substances. Aims: This randomized, placebo-controlled, proof-of-concept study (NCT02327013) evaluated the efficacy of a multimodal antidepressant, vortioxetine, in the treatment of ADHD, using a two-stage sequential parallel comparison design… 

Figures and Tables from this paper

Vortioxetine Add-On to Methylphenidate for the Treatment of Symptoms of Sickness Behavior in Attention-Deficit Hyperactivity Disorder: Report of Two Cases

The cases presented here suggest that vortioxetine could also be an effective option for ADHD treatment in childhood and adolescence, warranting further investigation of its potential benefits as both a monotherapy and adjunctive therapy to stimulants.

Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD

Given the high effect size found in RCTs of stimulants in terms of efficacy on ADHD core symptoms, it is unlikely that these novel agents will show better efficacy than stimulants, at the group level, however, they may offer comparable or better tolerability.

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

A review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years for the pharmacological treatment of ADHD found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients.

Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents

This review profiles alternatives to Schedule II (CII) stimulants that are in clinical stages of development (Phase 2 or 3).

The Treatment of Adult ADHD: Complexity at Hand

In order to provide specific and targeted interventions, it should be mandatory to address all dimensions (i.e., inattention, impulsivity, hyperactivity, emotional dysregulation) that appeared most affected when the patient asked for help.

Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials.

The findings show that although the overall rate of intentional non-adherence does not change over the course of a clinical trial, study volunteers who deliberately chose not to take their first dose had a mean intentionalNon-adherent rate five times higher than that observed among those who were first dose adherent.

DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men

In an 8-week optimization pilot with 20 YMSM in San Francisco and Atlanta, the app was found to be highly acceptable, with median System Usability Scale scores in the “excellent” range, and app use was high, with Median PrEP adherence of 91% based on aDOT-confirmed dosing.



Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials

Overall, ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Two studies early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD and was found to be well tolerated.

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.

A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy.

It is suggested that DMI can be an effective treatment in the management of pediatric patients with ADDH, including patients who failed to respond to stimulants.

Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology

The non-stimulant atomoxetine led to significant improvement in core ADHD symptomatology and should be considered as a viable pharmacological treatment option for ADHD.

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

In conclusion, Lu AA21004 was efficacious and well tolerated in the treatment of elderly patients with recurrent major depressive disorder and showed superiority to placebo in cognition tests of speed of processing, verbal learning and memory.

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

Vortioxetine represents an important treatment for MDD-related cognitive dysfunction and significantly improved cognition, independent of depressive symptoms.

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.

Low-quality evidence that bupropion decreased the severity of ADHD symptoms and increased the proportion of participants achieving clinical improvement is found, suggesting a possible benefit in clinical improvement in adults with ADHD.

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

In this study of MDD adults who self-reported cognitive dysfunction, vortioxetine significantly improved cognitive function, depression, and functionality and was generally well tolerated.